China's First SPF Porcine Collagen Implant Approved, Marking Entry into High-Purity, High-Standard Era

Recently, the National Medical Products Administration (NMPA) issued the latest approval document, officially approving for market launch the “Collagen Implant” independently developed by Chengdu ChipBio Co., Ltd. (hereinafter referred to as “ChipBio”). Registration Certificate Number:NMPA Registration No. 20263130023

This product isThe first approved in mainland China SPF Porcine-Derived Collagen Implant，The approval of ChipBio Collagen not only enriches the domestic supply of SPF porcine collagen but also marks that Chinese collagen technology, represented by “xenotransplantation-grade raw materials” and “National Grade I Reference Materials,” has officially entered a new stage of high-standard, high-purity industrialization.

In recent years, as the medical aesthetics industry shifts from “unregulated expansion” to “high-quality development,” compliance has become an irreversible foundational principle. Under stringent regulatory oversight, the National Medical Products Administration (NMPA) has increasingly tightened approval standards for Class III medical devices, with particular emphasis on animal-derived implantable materials, where raw material safety and viral control are paramount considerations in the review process.

For a long time, the domestic high-end porcine collagen implant market has been dominated by brands from Taiwan, China. The approval of Chengdu ChipBio marks an industry milestone:

Achieved a “zero breakthrough” for mainland Chinese enterprises in the field of SPF (Specific Pathogen-Free) porcine-derived collagen implants, reshaped the market landscape for high-end collagen, and demonstrated that upstream Chinese medical aesthetics companies now possess the complete closed-loop capability—from source raw material control to high-end formulation development—driving the industry’s transition from mere “product approval” to “technology leadership.”

On the foundation of compliance, the core competitiveness of products returns to technology itself. The reason why ChipBio has become the focus of the industry lies in its "raw material source"with“The Dual Innovation of ‘Emerging Technologies’.”

Unlike conventional animal-derived sources, the core raw material of ChipBio Collagen is sourced fromXenotransplantation-specific SPF Pig Population，Under fully enclosed, isolated rearing conditions and a comprehensive traceability system, the risks of zoonotic diseases and viral contamination are eliminated at the source. This rigorous raw material selection process addresses the primary concern of physicians and aesthetic patients regarding animal-derived materials: safety.

Collagen components after secondary fibroblast technology can construct a dense and uniform fibrous network structure after being implanted into the human body. Clinical evidence confirms that after product implantationHardly induces inflammatory response, capable of providing a stable scaffold for fibroblast adhesion and inducing the "organized neogenesis" of autologous collagen.

This “low-inflammation, high-induction” profile enables the product to provide immediate support while achieving long-lasting tissue rejuvenation when addressing dynamic wrinkles.

As a high-tech enterprise established in 2017, Chengdu ChipBio has not rested on the success of a single product but is committed to establishing technical standards for the industry.

Chengdu ChipBio's porcine type I collagen has recently been approved asThe First and Only National Grade I Reference Material for Collagen in China. This signifies that Chengdu ChipBio possesses absolute technical authority and leading capabilities in the detection, quantification, and quality control of collagen.

In terms of production capacity and R&D, Chengdu ChipBio boasts a Class 10,000 cleanroom GMP workshop and a Class 100 laminar flow isolation sterile filling production line, and has built a diversified product pipeline centered on “traceable animal tissue raw materials.”

The launch of ChipBio’s collagen implant demonstrates its profound expertise in biomaterials research and development. It is reported that multiple innovative devices under Chengdu ChipBio are currently undergoing clinical trials and regulatory submission processes. In the future, Chengdu ChipBio will continue to leverage “SPF porcine-derived biomaterials” as its core technology, consistently delivering innovative solutions driven by Chinese intelligent manufacturing across various fields, including medical aesthetics and urology.